Patents by Inventor Devin Sok

Devin Sok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12534516
    Abstract: Provided herein are anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: January 27, 2026
    Assignee: International AIDS Vaccine Initiative
    Inventors: Elise Landais, Devin Sok
  • Publication number: 20250296985
    Abstract: The present invention relates to seven novel neutralizing human monoclonal antibodies (mAbs) THSC20.HVTR04, THSC20.HVTR06, THSC20.HVTR11, THSC20.HVTR26 THSC20.HVTR39, THSC20.HVTR55 and THSC20.HVTR88 and their nucleotide sequences isolated from a convalescent individual of Indian origin by antigen (RBD)-specific single B cell sorting and cloning of variable heavy and light IgG chain genes. The isolated mAbs demonstrate neutralization of wild type Wuhan strain and the following variants of concern: South African variant of concern (B.1.351), UK variant of concern (B.1.1.7), Brazilian variant of concern (PI), Delta (B.1.617.2) and Omicron (B.1.1.529) with exception of THSC20.HVTR39 unable to neutralize Gamma (P1). Of these THSC20.HVTR04 is able to potently neutralize Omicron BA.2 and BA.4/BA.5, THSC20.HVTR06 is able to neutralize Omicron BA.1, BA.2 and BA.5 with low potency, THSC20.HVTR11 potently neutralizes Omicron BA.1 and BA.2 and THSC20.HVTR26 neutralizes Omicron BA. 1 only with moderate potency.
    Type: Application
    Filed: August 24, 2022
    Publication date: September 25, 2025
    Inventors: Jayanta BHATTACHARYA, Nitin HINGANKAR, Payel DAS, Suprit DESHPANDE, Pallavi KSHETRAPAL, Ramachandran THIRUVENGADAM, Amit AWASTHI, Abbas Rizvi ZAIGHAM, Devin SOK
  • Publication number: 20240109956
    Abstract: The present disclosure relates to methods for generating broadly neutralizing bovine anti-HIV Env antibodies, compositions comprising the broadly neutralizing bovine antibodies, and methods of treatment or prevention of HIV using the broadly neutralizing bovine antibodies. In certain embodiments, a broadly neutralizing bovine antibody comprises a polyclonal F(ab) or F(ab?)2 fragment. In certain embodiments, a broadly neutralizing bovine antibody comprises a humanized bovine monoclonal antibody.
    Type: Application
    Filed: September 19, 2023
    Publication date: April 4, 2024
    Inventors: Devin SOK, Dennis R. BURTON, Vaughn V. SMIDER, Ian WILSON, Michael CRISCITIELLO, Waithaka MWANGI
  • Publication number: 20230357364
    Abstract: The present application is directed to recombinant monoclonal antibodies, or antigen fragments thereof that bind a Spike protein of SARS-CoV-2. Methods of using the antibodies to treat or prevent SARS-CoV-2 (COVID-19) are also disclosed.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 9, 2023
    Inventors: Devin Sok, Joseph Jardine, Elise Landais, Dennis Burton, Tom Rogers, Fangzhu Zhao, Deli Huang
  • Patent number: 11795211
    Abstract: The present disclosure relates to methods for generating broadly neutralizing bovine anti-HIV Env antibodies, compositions comprising the broadly neutralizing bovine antibodies, and methods of treatment or prevention of HIV using the broadly neutralizing bovine antibodies. In certain embodiments, a broadly neutralizing bovine antibody comprises a polyclonal F(ab) or F(ab?)2 fragment. In certain embodiments, a broadly neutralizing bovine antibody comprises a humanized bovine monoclonal antibody.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 24, 2023
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Devin Sok, Dennis R. Burton, Vaughn V. Smider, Ian Wilson, Michael Criscitiello, Waithaka Mwangi
  • Publication number: 20230134571
    Abstract: The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 4, 2023
    Inventors: Devin SOK, Dennis R. BURTON, Joseph G. JARDINE
  • Publication number: 20210355197
    Abstract: The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.
    Type: Application
    Filed: October 21, 2019
    Publication date: November 18, 2021
    Inventors: Elise LANDAIS, Devin SOK
  • Publication number: 20210292396
    Abstract: The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.
    Type: Application
    Filed: July 26, 2019
    Publication date: September 23, 2021
    Inventors: Devin SOK, Joseph JARDINE
  • Publication number: 20200165324
    Abstract: The present disclosure relates to methods for generating broadly neutralizing bovine anti-HIV Env antibodies, compositions comprising the broadly neutralizing bovine antibodies, and methods of treatment or prevention of HIV using the broadly neutralizing bovine antibodies. In certain embodiments, a broadly neutralizing bovine antibody comprises a polyclonal F(ab) or F(ab?)2 fragment. In certain embodiments, a broadly neutralizing bovine antibody comprises a humanized bovine monoclonal antibody.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 28, 2020
    Inventors: Devin SOK, Dennis R. BURTON, Vaughn V. SMIDER, Ian WILSON, Michael CRISCITIELLO, Waithaka MWANGI
  • Patent number: 10093720
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 9, 2018
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
    Inventors: Dennis R. Burton, Marit J. van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
  • Publication number: 20150361160
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Application
    Filed: June 5, 2015
    Publication date: December 17, 2015
    Inventors: Dennis R. Burton, Marit J. van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
  • Patent number: RE49037
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: April 19, 2022
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, Cornell University
    Inventors: Dennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
  • Patent number: RE50268
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: January 14, 2025
    Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, Cornell University
    Inventors: Dennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok